Compare iShares 0 3 Month Treasury Bond ETF (SGOV) vs BIO-TECHNE Corp (TECH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares 0 3 Month Treasury Bond ETF vs BIO-TECHNE Corp — how do they compare? iShares 0 3 Month Treasury Bond ETF trades at $100.51 (market cap $114.40B), while BIO-TECHNE Corp trades at $72.46 (market cap $11.36B). The key difference: iShares 0 3 Month Treasury Bond ETF is far larger — about 10.1× BIO-TECHNE Corp's market cap, and BIO-TECHNE Corp pays a 0.44% dividend while iShares 0 3 Month Treasury Bond ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold iShares 0 3 Month Treasury Bond ETF for 50 Days and BIO-TECHNE Corp for 63 Days on average.
| SGOV | TECH | |
|---|---|---|
Market Cap | $114.40B | $11.36B |
Volume | 18,879,081 | 5,390,331 |
Sector | Fixed Income | Health |
52-Week High | $100.72 | $72.61 |
52-Week Low | $100.28 | $43.31 |
Typical Hold Time | 50 Days | 63 Days |
Enterprise Value | — | $11.39B |
Dividend Yield | — | 0.44% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SGOV (iShares 0-3 Month Treasury Bond ETF) trades at $100.465 with minimal daily movement, reflecting its stable Treasury bill holdings. The ETF shows bearish technical signals with 17 sell indicators versus 4 buy signals, though RSI levels suggest potential oversold conditions. Recent institutional activity includes Envestnet Asset Management reducing its position by 13.2% in Q2 2026. The fund continues its consistent dividend payments with recent distributions of $0.30-$0.31 per share.
SGOV provides exposure to ultra-short-term Treasury securities, offering stability amid bond market volatility. The ETF faces headwinds from rising interest rates but benefits from flight-to-quality flows. Key risks include interest rate sensitivity and potential yield compression if Fed policy shifts dovishly. Current technical weakness may present entry opportunities for income-focused investors seeking capital preservation.
TECH trades at $72.53, near its 52-week high of $72.70, with a bullish technical signal from moving averages. The company reported mixed quarterly earnings, beating in Q4 2025 and Q2 2026 but missing in Q1 2026. Revenue for 2025 was $1.22B, with a net income margin of 14.97%. Valuation ratios are elevated, with a P/E of 62.46 and P/S of 9.36. A significant development is the shareholder-approved acquisition by Merck KGaA at $73.00 per share, pending completion.
The outlook is heavily influenced by the pending acquisition, offering a near-term price ceiling. Fundamentals show solid profitability but high valuation multiples. Risks include acquisition deal completion uncertainty and integration challenges. Analyst sentiment is mixed with no sell ratings, but the consensus price target of $65.78 suggests limited upside from current levels, making the stock a hold pending acquisition closure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About iShares 0 3 Month Treasury Bond ETF
SGOV provides exposure to ultra-short-term U.S. Treasury bills with maturities of three months or less. It functions as a high-liquidity cash alternative, seeking to provide current income while maintaining a stable net asset value and minimal interest rate risk.
Read more on SGOV →About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →
